US 12,403,336 B2
Betacorona virus mRNA vaccines
Giuseppe Ciaramella, Sudbury, MA (US); and Sunny Himansu, Winchester, MA (US)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Filed by ModernaTX, Inc., Cambridge, MA (US)
Filed on Dec. 23, 2024, as Appl. No. 19/000,472.
Application 19/000,472 is a continuation of application No. 18/762,372, filed on Jul. 2, 2024, granted, now 12,208,288.
Application 19/000,472 is a continuation of application No. 18/762,384, filed on Jul. 2, 2024.
Application 19/000,472 is a continuation of application No. 18/762,296, filed on Jul. 2, 2024.
Application 18/762,384 is a continuation of application No. 18/528,323, filed on Dec. 4, 2023.
Application 18/762,372 is a continuation of application No. 18/528,323, filed on Dec. 4, 2023.
Application 18/762,296 is a continuation of application No. 18/528,323, filed on Dec. 4, 2023.
Application 18/528,323 is a continuation of application No. 16/897,734, filed on Jun. 10, 2020, granted, now 11,872,278, issued on Jan. 16, 2024.
Application 16/897,734 is a continuation of application No. 16/368,270, filed on Mar. 28, 2019, granted, now 10,702,599, issued on Jul. 7, 2020.
Application 16/368,270 is a continuation of application No. 16/040,981, filed on Jul. 20, 2018, granted, now 10,272,150, issued on Apr. 30, 2019.
Application 16/040,981 is a continuation of application No. 15/674,599, filed on Aug. 11, 2017, granted, now 10,064,934, issued on Sep. 4, 2018.
Application 15/674,599 is a continuation of application No. PCT/US2016/058327, filed on Oct. 21, 2016.
Claims priority of provisional application 62/247,362, filed on Oct. 28, 2015.
Claims priority of provisional application 62/247,483, filed on Oct. 28, 2015.
Claims priority of provisional application 62/247,297, filed on Oct. 28, 2015.
Claims priority of provisional application 62/247,394, filed on Oct. 28, 2015.
Claims priority of provisional application 62/245,031, filed on Oct. 22, 2015.
Claims priority of provisional application 62/244,837, filed on Oct. 22, 2015.
Claims priority of provisional application 62/244,813, filed on Oct. 22, 2015.
Claims priority of provisional application 62/244,802, filed on Oct. 22, 2015.
Claims priority of provisional application 62/244,946, filed on Oct. 22, 2015.
Prior Publication US 2025/0121221 A1, Apr. 17, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 31/14 (2006.01); A61K 39/12 (2006.01); A61K 39/155 (2006.01); A61K 39/215 (2006.01); A61P 11/00 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 39/155 (2013.01); A61K 39/215 (2013.01); A61P 11/00 (2018.01); A61P 31/14 (2018.01); C07K 16/10 (2013.01); C07K 16/1002 (2023.08); C07K 16/1027 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/6018 (2013.01); A61K 2039/70 (2013.01); C07K 2317/76 (2013.01); C12N 2760/18034 (2013.01); C12N 2760/18334 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18634 (2013.01); C12N 2770/20034 (2013.01); Y02A 50/30 (2018.01)] 8 Claims
 
1. A method of vaccinating a human subject against a betacoronavirus, the method comprising administering to the human subject a dose of a vaccine comprising a messenger ribonucleic acid (mRNA) formulated in a lipid nanoparticle comprising 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid, wherein the mRNA comprises an open reading frame encoding a full-length betacoronavirus spike protein, wherein the open reading frame comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine, wherein the dose is administered intramuscularly and comprises from 20-50 μg of the mRNA, and wherein the vaccine has an efficacy against betacoronavirus infection of at least 90%, wherein betacoronavirus infection is determined using polymerase chain reaction (PCR).